Active, not recruitingPHASE1, PHASE2NCT02935517
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)
Studying Achromatopsia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beacon Therapeutics
- Principal Investigator
- David Jacobs, MD, MBAApplied Genetics Technologies Corporation
- Intervention
- AGTC-402(biological)
- Enrollment
- 24 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2017 – 2026
Study locations (6)
- VitreoRetinal Associates, Gainesville, Florida, United States
- Bascom Palmer Eye Institute, Miami, Florida, United States
- Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
- Cincinnati Eye Institute, Cincinnati, Ohio, United States
- Casey Eye Institute, Oregon Health and Sciences University, Portland, Oregon, United States
- Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02935517 on ClinicalTrials.govOther trials for Achromatopsia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07085533Natural History Study of Inherited Retinal DiseasesZhongmou Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02599922Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)Beacon Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02610582Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked AchromatopsiaSTZ eyetrial